News & Media / Press Releases

WBB Securities Named Co-Manager on Omeros Corporation Underwriting

March 19, 2014

Omeros closes $40.25 million in underwritten public offering

Continue Reading

WBB Securities Retained as Financial Advisor to Athersys, Inc.

January 10, 2014

Athersys announces $20.5 million registered direct financing to fund ongoing clinical trials in regenerative medicine

Continue Reading

WBB Securities Sponsors BioCentury’s 20th Annual NewsMakers Conference

October 1, 2013

Executive Teams of Emerging Biotech Companies to Present to Investor Community

Continue Reading

Financial Times and Thomson Reuters name Steve Brozak as a 2013 StarMine

August 22, 2013

WBB’s Steve Brozak named “Top Stock Picker” in Pharmaceuticals

Continue Reading

WBB Securities Retained as Financial Advisor to Navidea Biopharmaceuticals, Inc.

June 26, 2013

Navidea closes $25 million debt financing with GE Capital to finance and manage commercialization of approved radiopharmaceutical

Continue Reading

WBB Securities Retained as Financial Advisor to Cempra, Inc.

June 19, 2013

Cempra closes $54.2 million financing to support its efforts to develop and commercialize novel antibiotic treatments

Continue Reading

WBB Sponsors 2013 BIO CEO

February 1, 2013

Conference is focused on established and emerging publicly traded and select private biotech companies

Continue Reading

WBB Securities’ Steve Brozak Speaks on Drug Development Costs at Bloomberg Healthcare Innovations Conference

October 2, 2012

Bloomberg Healthcare Conference aims to identify promising innovations in the healthcare space

Continue Reading

WBB Securities Sponsors 19th Annual NewsMakers in the Biotech Industry Conference

September 4, 2012

Executive Teams of Emerging Biotech Companies to Present to Investor Community

Continue Reading

WBB Securities’ Brozak to Co-Present at 2012 Biodefense Vaccines and Therapeutics Summit

June 6, 2012

Summit will provide progress of various countermeasures from the Public Health Emergency Medical Countermeasures Enterprise Review and how they will impact biodefense

Continue Reading